Evaluating reduction of opioid and barbiturate use following rimegepant initiation in the United States

Study identification

• EU PAS number:
  EUPAS1000000755
• Study ID:
  1000000755
• Official title and acronym:
  Evaluating reduction of opioid and barbiturate use following rimegepant initiation in the United States
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This is a non-interventional, retrospective, observational, cohort study that will assess changes in opioid and barbiturate utilization after initiation of rimegepant among adults in the US. This study will analyze an administrative claims database (IQVIA PharMetrics Plus) with information on individuals in the US with commercial, managed Medicare, or managed Medicaid health plans. This database includes information captured in medical and pharmacy claims (eg, dates of service, diagnosis codes, procedure codes, medications dispensed, demographics, health plan enrolment).
• Study status:
  Ongoing

Research institutions and networks

Institutions

Pfizer

Study timelines

Date when funding contract was signed

Planned:01/07/2023

Actual:01/07/2023

Study start date

Planned:21/08/2023

Actual:21/08/2023

Date of final study report

Planned:01/03/2026

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable